Pliant Therapeutics Net Income 2019-2021 | PLRX

Pliant Therapeutics net income from 2019 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Pliant Therapeutics Annual Net Income
(Millions of US $)
2020 $-42
2019 $-7
2018 $-35
Pliant Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-23
2021-03-31 $-23
2020-12-31 $-8
2020-09-30 $-17
2020-06-30 $-17
2020-03-31 $0
2019-12-31 $42
2019-09-30 $-15
2019-06-30 $-17
2019-03-31 $-15
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.647B $0.042B
Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00